Men going bald turn to 'new Botox' for hair loss treatment
The cure for baldness has long been a scientific enigma.
Yet advanced treatment options and hair-loss clinics have continued to emerge — and researchers are making progress on finding fixes for balding.
UCLA scientists recently alerted a "breakthrough" discovery involving a molecule named PP405 that can "waken long-slumbering but undamaged" hair follicles, according to a press release.
Cure For Men's Hair Loss Could Be Found In Sugar Stored In The Body, Study Suggests
In a 2023 clinical trial, researchers found that applying PP405 as a topical medicine to the scalp at bedtime showed "statistically significant" results.
They believe this treatment will produce "full 'terminal' hair rather than the peach fuzz variety."
Read On The Fox News App
William Lowry, Ph.D., a co-researcher at UCLA Broad Stem Cell Research Center, told Fox News Digital that although this research is promising, "cure is a strong word."
"There are only two FDA-approved treatments for androgenetic alopecia (AGA, or pattern baldness): minoxidil and finasteride," he said in an interview.
"They are both limited in efficacy and improve hair in only a portion of patients who take them."
These 5 Balding And Hair Loss Treatments Could Help Ensure A Healthy Scalp, Experts Say
Other treatment options include supplements, red light therapy, platelet-rich plasma injections and hair transplantation, Lowry said, although these have not undergone "definitive clinical trials and can be expensive, time-consuming and limited in efficacy."
He added, "None of these are curative, meaning none of them permanently restore all hair lost due to AGA."
Lowry and his fellow researchers have discovered that hair follicle stem cells have a "distinct metabolism from other cells in the follicle."
He said, "We found that promoting this metabolism can accelerate stem cell activation, which makes new hairs grow. We subsequently developed drugs that can drive this effect in various models of hair loss that reflect the multifactorial drivers of androgenetic alopecia in patients."
Hair Loss And Prostate Medication Could Also Reduce Heart Disease Risk, Study Finds
PP405 has become the leading candidate for hair-loss treatment as part of this new class of drugs.
"We are excited about the opportunity to bring a novel treatment option to patients with hair loss based on strong science and rigorous clinical trials," he said.
"Additionally, because the mechanism of action we discovered is distinct from previous approaches, it can potentially be used in combination with other therapies."
Brendan Camp, M.D., a Manhattan-based dermatologist, told Fox News Digital in an interview that hair loss is a condition that "affects many and can have a negative impact on people's psychosocial health."
So identifying a potential new hair-loss treatment is an "exciting step for patients and providers in the management of what can otherwise be a difficult condition to treat."
Camp agreed there is an "unmet need" for hair-loss treatment and that there's growing interest in providing solutions and offering hair restoration services more widely.
Hair Loss? Gut Health Issues? Dr. Nicole Saphier Reveals Smart Fixes
As cosmetic injections such as Botox and fillers have continued to be popular anti-aging and beauty treatments, hair-loss and restoration med spas are similarly surfacing nationwide.
The clinics offer a variety of services for men and women given the availability of modern options.
Dr. Amy Spizuoco, DO, of True Dermatology in New York, dubbed balding treatments in this capacity the "new Botox."
"With advances in treatments like minoxidil, finasteride, PRP (platelet-rich plasma) therapy, hair transplants and the latest stem cell research, hair restoration has become more accessible and effective," she told Fox News Digital.
Click Here To Sign Up For Our Health Newsletter
"And much like Botox is used preventatively, younger people are tackling hair loss at the first signs rather than waiting until it's severe."
Camp added that while there are many hair-loss treatment options available, the response will look different for each person.
"When looking for a treatment, stick to those with a well-established body of evidence and data to support their use, such as minoxidil, finasteride and spironolactone (in the case of female-pattern hair loss)," he advised.
For more Health articles, visit foxnews.com/health
And be sure to get "the advice of a board-certified dermatologist when at-home treatments are not effective," he also said.
These treatments are "typically used indefinitely" and should be tested for three to four months before being ruled out as effective or not, the dermatologist added.
Spizuoco said that while hair loss is common, early intervention with the right treatment plan can "significantly slow it down or possibly reverse it."Original article source: Men going bald turn to 'new Botox' for hair loss treatment
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Miami Herald
an hour ago
- Miami Herald
Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs
June 17 (UPI) --Eli Lilly and Company said Tuesday it will buy out Boston-based Verve Therapeutics Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs. Indianapolis-based Eli Lilly announced its definitive agreement to acquire Verge, a gene-editing startup, for up to $1.3 billion at $10.50 a share -- a premium of 67.5% at last closing -- with the goal to boost Verve's budding pipeline of medicine designed to target and treat a wide-range of cardiovascular-related health issues. "Lilly is eager to welcome our Verve colleagues to Lilly and continue the development of these promising potential new medicines aimed at improving outcomes for patients with cardiovascular disease and addressing the significant unmet medical need in this space," said Ruth Gimeno, Lilly's group VP for diabetes and metabolic research and development. Under the agreement terms, the transaction will not be subject to any financing conditions and will include a nearly $1 billion upfront payout plus a further $300 million based on certain clinical milestones. The deal is expected to close by this year's third quarter subject to conditions. Verve's medical treatment program, according to a Gimeno, could "shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment." Meanwhile, stock shares in Verve jumped 76% to over $11 in premarket trading Tuesday morning while Lilly stock value fell 1%. A years-long study from 2010-2022 released in November revealed how the number of dead via cardiovascular disease had surged among adults ages 25 to 64 living in rural areas. Verve uses a next gen type of gene editing which erases and rewrites a specific gene letter. Lilly's Gimeno says the Verve-102 program, which is currently in its Phase 1b clinal trial study and fast-tracked for FDA approval, "has the potential" to be the first "in vivo" gene editing therapy deployed to treat a broad population of patients seeking treatment for cardiac issues. 102 may be utilized for patients seeking treatment for heterozygous familial hypercholesterolemia (HeFH), which is a subset of ASCVD affecting 1 in 250 people. On Tuesday, Verve's chief noted how in just seven years that the Verve team had progressed three in vivo gene editing products with two currently in clinics. "Verve was founded with one mission in mind: transform the treatment of cardiovascular disease from chronic care to a one-dose future," said Verve Therapeutics co-founder and CEO Dr. Sekar Kathiresan. Copyright 2025 UPI News Corporation. All Rights Reserved.
Yahoo
an hour ago
- Yahoo
Materna Medical Announces Ellora™ and Additional Close on $20M Series B2
MOUNTAIN VIEW, Calif., June 17, 2025--(BUSINESS WIRE)--Materna Medical, Inc., a leading innovator in women's pelvic health solutions, has announced the completion of a recent close within an ongoing $20 million Series B2 financing round. The round welcomed new funds GLIN Impact Capital, Wealthing VC Club, and Citrine Angels, and was led by InnovaHealth Partners and other key existing investors Wavemaker Three-Sixty Health, Kimera Limited, Women's Venture Capital Fund, and Golden Seeds. "As we celebrate the addition of these new funds to our investment team, we are also excited to announce the new commercial name for our second product, Ellora™ (formerly Materna Prep), aiming to transform the standard of care in labor and delivery," commented Tracy MacNeal, Chief Executive Officer for Materna Medical "Over 20 of the top hospitals in the US have been incredible partners in the EASE trial for Ellora™, which will be the basis of our FDA De Novo submission this summer." For more information on Materna Medical, visit About Materna Medical Materna Medical is a novel OBGYN platform company defining a $25B market with core technologies addressing unmet needs in women's pelvic health. With headquarters in Mountain View, California, Materna pulls from the top minds in MedTech to truly transform the standard of care in OBGYN. With a diverse team of engineers, scientists, researchers, and commercial leaders, Materna Medical's mission is to empower women to protect their pelvic health. Our first product, Milli™, is vaginal dilator to support patients suffering from vaginismus and related painful sex. In 2019, the Milli device launched as a wellness trainer and, in 2023, received FDA clearance to sell over the counter, enabling streamlined access to people suffering from vaginismus. Milli outcomes have been studied in a post-market prospective virtual study named POMPOM. Materna's second product, Ellora™, is an investigational device used during labor and is intended to reduce pelvic floor muscle injury during vaginal delivery. This product is being studied in the EASE trial, a large, randomized controlled trial in 20 top US hospitals. Materna aims to transform the standard of care in labor and delivery by protecting pelvic floor health for moms. View source version on Contacts Debbie DonovanHead of Commercial OperationsMaterna Medical, Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Dental Care of Stamford announces Breakthrough Bite-Based Treatment During Migraine Awareness Month
STAMFORD, CT, June 17, 2025 (GLOBE NEWSWIRE) -- As Migraine Awareness Month shines a spotlight on one of the most debilitating chronic conditions in the world, Dr. Jerry Simon, a leading dental expert in craniofacial pain and neuromuscular dentistry, is offering a fresh perspective on how migraines could be a dental issue hiding in plain sight?Migraines affect more than 35 million Americans annually, often derailing daily life with searing pain, nausea, and visual disturbances. Despite modern medicine's advancements, many patients still struggle to find a sustainable solution, leaving them stuck in a cycle of temporary relief and recurring agony. Dr. Simon believes the answer for many could be closer than they think , right inside their mouth. 'Too many people suffer unnecessarily because the true cause of their pain is being overlooked,' says Dr. Simon. 'What if the root of your migraines isn't neurological, but dental?' The Dental Link to Migraines: An Overlooked Connection Dr. Simon, founder of Dental Care of Stamford and innovator of the FDA-approved Best-Bite Discluder™, is challenging conventional approaches by investigating a common yet often missed culprit: bite imbalances. According to his research and clinical practice, nearly 75% of chronic migraines, neck aches, facial discomfort, and tension headaches stem from misaligned bites also known as malocclusion. This overlooked factor causes the muscles in the jaw and face to overcompensate, leading to inflammation and persistent pain. 'You use your mouth all day—to chew, talk, breathe, even clench unconsciously. If your teeth don't come together properly, your jaw muscles are constantly adjusting, and over time, that stress adds up,' Dr. Simon explains. Quick, Non-Invasive Diagnostic Tool Offers New Path to Relief To pinpoint whether migraines are bite-related, Dr. Simon developed a diagnostic device known as the Best-Bite Discluder™, which helps determine within minutes if a patient's bite is contributing to their head pain. The small, comfortable appliance temporarily disengages the back teeth to relieve pressure. If patients experience immediate relief, even if momentary, it signals that the bite may be the root cause. 'The most powerful moment is watching someone realize that their pain doesn't have to be permanent,' says Dr. Simon. 'If the discluder test helps, it gives us a clear path forward.' Real Stories, Real Relief Former patient S.W., once plagued by chronic migraines and disappointed by countless specialist visits and inconclusive scans, found hope with Dr. Simon. 'I had migraines forever. Undergone endless tests from multiple doctors with no answers. Dr. Simon suggested my teeth could be the issue & then tested my bite. After a few visits, I was already feeling great! He gave me my life back, pain-free!' A Collaborative, Personalized Approach If a bite issue is confirmed, Dr. Simon and his team at Dental Care of Stamford create a customized treatment plan tailored to each patient's unique physiology. This plan may involve bite adjustments, physical therapy, and advanced dental procedures aimed at achieving harmony between the jaw and surrounding muscles - offering lasting relief without reliance on medications or invasive treatments. Raising Awareness, Changing Lives During Migraine Awareness Month, Dr. Simon hopes to educate the public about this little-known yet significant link between dental health and migraines. His goal is to help people who feel like they've exhausted every option and are still searching for answers. 'Migraines are not something people should have to just live with,' says Dr. Simon. 'By identifying and treating the actual source of pain—instead of just masking symptoms - we can truly transform lives.' Schedule Your Consultation Today If you or a loved one has struggled with chronic headaches or migraines, there's no need to wait any longer. Relief could be a simple consultation away. Call (203) 324-6171 or visit CONTACT: Media Contact: Dental Care of Stamford Phone: (203) 324-6171 Email: FrontDesk@ in to access your portfolio